Register | Login
Intellectual Property Today
RFC Express - Document Management System
2013 Top Patent Firms
2013 Top Trademark Firms
Current Issue

Advertising Opportunities

Click Here

Email A Friend Back to Archived News

Advaxis Receives US Patent and Trademark Office Approval on Act-A Protein Patent-Pending Rights

Thursday, May 28, 2009

Compositions and Methods for Enhancing Immunogenicity of Antigens

North Brunswick, NJ -- The US Patent and Trademark office approved Advaxis Incorporated (OTCBB: ADXS) patent-application Compositions and Methods for Enhancing the Immunogenicity of Antigens (Application # US2005/0118184 A1). This patent application covers the use of Listeria monocytogenes (Lm) protein ActA and fragments of this protein for use in the creation of antigen fusion proteins.

The ActA protein has been found to possess immuno-adjuvant properties. Advaxis’ proprietary technology is based, in part, upon bioengineered Lm that secretes antigen-adjuvant fusion proteins. The vaccines that Advaxis is developing, in both current and future clinical trials, make use of antigens fused to another Lm protein, Listeriolysin-O.

The addition of the ActA protein to this portfolio of proprietary technology increases the ability to create specific and effective vaccines by using a variety of antigens and adjuvant proteins to target different types of cancers and infectious disease indications.

The patent was authored by Advaxis Scientific Founder Dr. Yvonne Paterson and members of her laboratory, and licensed to Advaxis by the University of Pennsylvania.

"We are building a comprehensive tool kit to utilize the unique abilities of Listeria as an immunologically active delivery vehicle," commented Advaxis CEO Thomas A. Moore. "By creating new strains of Listeria and developing new methods of creating active antigen-fusion proteins we have developed the ability to select the optimal technology to create specific vaccines to treat for many different cancers or infectious disease indications."

About Advaxis, Inc.

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.

For further information on the Company, please visit:

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.

Back to Archived News
Looking for...

  © Copyright 2013 Intellectual Property Today
Download Adobe Reader for free